A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing (Q56828539)

article

Language	Label	Description	Also known as
English	A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing	article

Statements

instance of

scholarly article

0 references

title

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing (English)

0 references

Lars L. Gustafsson

2

0 references

author name string

Brian Godman

series ordinal

1

0 references

publication date

16 January 2013

0 references

published in

Applied Health Economics and Health Policy

0 references

volume

11

0 references

page(s)

79-82

0 references

issue

1

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s40258-012-0008-7

0 references

cites work

A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Forecasting drug utilization and expenditure in a metropolitan health region

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Potential savings without compromising the quality of care

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

How much will Herceptin really cost?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Balancing Big Pharma's books

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

International variability in the reimbursement of cancer drugs by publically funded drug programs

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Identifiers

DOI

10.1007/S40258-012-0008-7

0 references

PubMed ID

23322546

0 references

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing (Q56828539)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing (Q56828539)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search